Study of Palivizumab in Children with High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

Trial Identifier:	D4800L00014
Sponsor:	AstraZeneca
Start Date:	April 2025
Primary Completion Date:	April 2026
Study Completion Date:	April 2026
Condition:	Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.